(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
16 October 2025 (16.10.2025)

WIPO | PCT

(10) International Publication Number
WO 2025/217591 A1

(51) International Patent Classification:
C12N 15/63 (2006.01) *C12N 15/67* (2006.01)
A61K 48/00 (2006.01)

(21) International Application Number:
PCT/US2025/024390

(22) International Filing Date:
11 April 2025 (11.04.2025)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

63/633,522	12 April 2024 (12.04.2024)	US
63/679,518	05 August 2024 (05.08.2024)	US

(71) Applicant: **STRAND THERAPEUTICS INC.** [US/US]; 20 Overland Street, Suite A, Boston, Massachusetts 02215 (US).

(72) Inventors: **KITADA, Tasuku**; c/o Strand Therapeutics Inc., 20 Overland Street, Suite A, Boston, Massachusetts 02215 (US). **KHURANA, Jaspreet S.**; c/o Strand Therapeutics Inc., 20 Overland Street, Suite A, Boston, Massachusetts 02215 (US). **ARIAS ESCAYOLA, Dahyana**; c/o Strand Therapeutics Inc., 20 Overland Street, Suite A, Boston, Massachusetts 02215 (US). **ABIL, Zhanar**; c/o Strand Therapeutics Inc., 20 Overland Street, Suite A, Boston, Massachusetts 02215 (US). **POON, William**; c/o Strand Therapeutics Inc., 20 Overland Street, Suite A, Boston, Massachusetts 02215 (US). **MORAN, Colleen**; c/o Strand Therapeutics Inc., 20 Overland Street, Suite A, Boston, Massachusetts 02215 (US).

(74) Agent: **KIM, Ji Eun** et al.; STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C., 1101 K Street NW, 10th Floor, Washington, District of Columbia 20005 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *of inventorship (Rule 4.17(iv))*

Published:
— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*

WO 2025/217591 A1

(54) Title: HUMAN-DERIVED SYNTHETIC REGULATORS AND USES THEREOF

(57) Abstract: The present disclosure relates to mRNA therapeutics employing human derived payload regulators and target binding sites. These regulators and target binding sites operate within genetic circuits. The disclosed regulators allow for the control of payload expression within a desired cell type with reduced off-target effects and increased therapeutic specificity.